CB1584

CHO-K1 IndcynoVEGFR2

£5,000.00
£5,000.00
Tax included.
Out of Stock

CHO-K1 IndcynoVEGFR2 is an IndEx-2 stable cell line inducibly expressing full length cynomolgus macaque VEGFR2.

IndEx-2 is RoukenCells' proprietary inducible expression system that enables precise, dose-dependent control of one or two target antigens within your chosen cell line. Using orthogonal chemically induced proximity switches, antigen expression can be independently tuned across a biologically relevant range, creating custom cell models for target validation, assay development and therapeutic screening.

Download our technical presentation here for more information and case studies.

FOR RESEARCH USE ONLY

Packaging of Rouken Cells product on a white background.
Graph showing cynoVEGFR2 receptors per cell against inducer concentration in logarithmic scale.
Graph showing cynoVEGFR2 expression with non-induced and CHO-K1 parental data, labeled 'Inducer concentration'.
  • Packaging of Rouken Cells product on a white background.
  • Graph showing cynoVEGFR2 receptors per cell against inducer concentration in logarithmic scale.
  • Graph showing cynoVEGFR2 expression with non-induced and CHO-K1 parental data, labeled 'Inducer concentration'.
Packaging of Rouken Cells product on a white background.
Graph showing cynoVEGFR2 receptors per cell against inducer concentration in logarithmic scale.
Graph showing cynoVEGFR2 expression with non-induced and CHO-K1 parental data, labeled 'Inducer concentration'.
Specification
Inducible Receptor
cynoVEGFR2
CD Designation
CD309
Gene name
KDR
Aliases
CD309, KDR, FLK1
Uniprot ID
G7P5T2
Receptor Species
Macaca fascicularis
Cell Line Background
CHO-K1
Target Information and Further Details
VEGFR2, encoded by the KDR gene on chromosome 4q12, is a receptor tyrosine kinase of the VEGF receptor family. It is the principal mediator of VEGF-A signalling, driving angiogenesis through activation of downstream pathways including MAPK and PI3K/AKT. VEGFR2 promotes endothelial cell proliferation, migration, and survival.
VEGFR2 is highly expressed on vascular endothelium in tumours, where VEGF/VEGFR2 signalling supports tumour angiogenesis and progression. Therapeutics targeting VEGFR2 include monoclonal antibodies (e.g., ramucirumab), tyrosine kinase inhibitors (e.g., sorafenib, axitinib), and VEGF-ligand inhibitors (e.g., bevacizumab), all of which have become central to anti-angiogenic therapy in cancer.
Performance Data
Graph showing cynoVEGFR2 expression with non-induced and CHO-K1 parental data, labeled 'Inducer concentration'.

Figure 1 – Histograms of cynoVEGFR2 Induction at 0-100 µM Inducer.

Graph showing cynoVEGFR2 receptors per cell against inducer concentration in logarithmic scale.

Figure 2 – Quantification of cynoVEGFR2 Induction at 0-100 µM Inducer.

* Cells were then stained with a labelled antibody and expression levels quantified using a bead-based quantification kit. Specific induction conditions should be further defined by the user. Cell line suitable for preclinical research and development use only.

Shipping Details

Supplied as 1 vial of >3 million viable cells.

* Please note that US import permits for CHO-K1 cell products are the responsibility of the US-based recipient/importer. RoukenCells is happy to provide supporting documentation (e.g. product descriptions and noninfectious statements) to assist with the import process.

Cell Line Datasheet

Access detailed product specifications, user guides and technical documentation in PDF format.

Download PDF

Related products

Take a moment to explore selections tailored just for you.

Explore Now